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ABSTRACT: A series of novel selenides bearing benzene-
sulfonamide moieties was synthesized and investigated for
their inhibition on six human (h) carbonic anhydrase (CA, EC
4.2.1.1) isoforms such as the physiologically relevant hCA I, II,
VA, VB, VII, and IX and the X-ray complex in adduct with
hCA II for some of them investigated. These enzymes are
involved in a variety of diseases including glaucoma, retinitis
pigmentosa, epilepsy, arthritis, metabolic disorders, and cancer.
The investigated compounds showed potent inhibitory action
against hCA VA, VII, and IX, in the low nanomolar range, thus
making them of interest for the development of isoform-
selective inhibitors and as candidates for various biomedical
applications.
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Diabetes is a chronic disease, and the number of people inthe world with the disease has risen from 108 million in
1980 to 422 million in 2014.1 Several complications of diabetes
associated with hyperglycemia lead to disrupt the micro-
vasculature of insulin-insensitive tissues such as the eye, nerve,
and brain.2 These complications are caused by oxidative stress
and lead to pericyte loss,3,4 disruption of the blood−brain
barrier (BBB),5,6 and cognitive decline.7−9 The BBB is
composed largely of endothelial cells in the microvasculature
of the central nervous system. In close proximity to endothelial
cells one finds cerebral pericytes, another type of cells vital for
the integrity of the BBB.10 Pericyte cells are especially
susceptible to oxidative stress, which leads to cell death by
apoptosis.11 One cause of oxidative stress is the overproduction
of superoxide as a byproduct during excess respiration caused
by produced influx of glucose in insulin sensitive tissues.2
Mitochondrial human carbonic anhydrases hCA VA and VB
(CAs, EC 4.2.1.1) play a central role in the metabolism of
pyruvate, by sustaining the rate of respiration12 as described in
Figure 1.
Pyruvate is the end-product of the glycolytic pathway
obtained by glucose in the cytosol. Pyruvate enters the
mitochondria where it is carboxylated to oxaloacetate. In this
step, the production of bicarbonate anion required for
carboxylation is produced by mitochondrial hCAs through
reversible reaction between water and carbon dioxide (CO2 +
H2O ⇔ HCO3
− + H+).17 Oxaloacetate, when entering the
Krebs cycle, produces FADH2 and NADH, which are carried
out to the electron transfer chain (ETC) to generate ATP. O2
−
is a byproduct of ETC reactions, and it is the precursor of all
ROS. The high activity of the Krebs cycle produces a high
potential of mitochondrial membrane, which inhibits the
transport of electrons to complex III, increasing the half-life
of the free radicals of the coenzyme Q and reducing O2 to O2
−.
Mitochondrial CA isoform VA was identified as one of the
major contributors to brain diabetic disease;13 moreover, it was
discover that hCAs IX and XII are recently implicated in
ischemia-induced cerebrovascular pathology,14 making these
enzymes attractive drug targets for obtaining agents that can
interfere with these deleterious processes. This may lead to
novel strategies to prevent diabetic complications in the brain
and possibly in other insulin-insensitive tissues. Sulfonamides
are the most widely investigated class of CAIs; among these,
the most investigated are acetazolamide (AAZ), zonisamide
(ZNS), and topiramate (TPM) as pharmacologic inhibitors of
mitochondrial hCAs15−17 as outlined in Figure 2.
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Topiramate, however, had several and serious side effects
owing to its ability to inhibit other metabolic pathways,18,19
among which, there are nonmitochondrial CA,20 and in many
cases, it is not well tolerated by patients. Thus, it is essential to
develop newer drugs with more selectivity and fewer side
effects.
Compound Design and Synthesis. The drug design, in
this study, starts with the idea to combine the sulfonamide
moiety as a typical zinc binding group (ZBG) with the
interesting antioxidant propriety of organo-selenium scaf-
folds.21−23 In the present study, we investigated different
selenides incorporating a benzenesulfonamide moiety as a
carbonic anhydrase inhibitor (CAI). The synthetic approach
toward the synthesis of diselenide 3 is shown in Scheme 1. The
diazonium salt of sulfanilamide was prepared by reaction of 1
with sodium nitrite in the presence of acid (Sandmeyer
reaction) and used as a key intermediate for the synthesis of
compound 2. Successively, the selenocyanate derivative 2 was
converted easily into the diselenide 3 as reported previously by
our group24 and outlined in Scheme 1.
Thereafter, 3 was reduced with NaBH4 to the corresponding
selenolate, which in turn was treated in situ with the appropriate
halo-alkyl moieties 4a−j, affording the selenides 5a−j in good
yields (Table 1).
As a further investigation, in order to propose an alternative
way to access the target compounds, we sought to achieve
selenides from the selenocyanate 2, thus avoiding the synthesis
of the diselenide 3. We were pleased to observe that selenides
5a−j were obtained by nucleophilic substitution with the
Figure 1. Mitochondrial CAs in ROS production and their role in
brain pericytes apoptosis.
Figure 2. Structures of pharmacologic mitochondrial hCAs inhibitors:
acetazolamide (AAZ), topiramate (TPM), and zonisamide (ZNS).
Scheme 1. Synthesis of Selenocyanate 2 and Diselenide 3
Bearing Benzenesulfonamide Moiety
Table 1. Synthesis of Selenides Bearing Benzenesulfonamide
Moieties, 5a−j
aYields refer to isolated products.
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selenolate, in situ generated by reducing 2, as reported in
Scheme 2.
In order to access a different benzenesulfonamide with a
seleno aromatic tail (9), the procedure started with synthesized
4-(bromomethyl)benzenesulfonamide 7 as reported in Scheme
3. Compound 7 was synthesized following the method of
Naganawa et al.25
Finally, the selenide 9 was obtained from the reduction of
diphenyldiselenide 8 with NaBH4 and was added in situ to
sulfonamide 7 to afford in good yield the selenide 9 as outlined
in Scheme 4.
Carbonic Anhydrase Inhibition. In this study was
investigated the CA inhibition profile compounds 2, 3, 5a−j,
and 9 against six human isoforms such as the physiologically
relevant CA I, II, VA, VB, VII, and IX by means of the stopped-
flow carbon dioxide hydration assay26 after a period of 15 min
of incubation of the enzyme and inhibitor solutions.27−31 Their
activities were compared to the standard CAIs acetazolamide
(AAZ) and topiramate (TPM) (Table 2).
One goal of this study was to generate compounds
containing organoseleno scaffolds with antioxidant properties
to improve selectivity of the targeting of mitochondrial hCA
(VA and VB) compared with the clinically used topiramate
inhibitor (TPM). For the preliminary investigation, we have
tested the key intermediates 2 and 3. We observed that the
replacement of a selenocyanate group by a diselenide was well
tolerated except for hCA I, so compound 3 displayed a constant
of inhibition in the micromolar range (Ki = 1522.7 nM). The
following structure−activity relationships (SARs) for selenides
5a−j and 9 were observed by analyzing CA inhibition profile in
Table 2. The inhibition profile of hCA I was comparable to
standards AAZ and TPM, except for 5d−f and 5i. These
compounds showed an activity more than 10 times greater for
5i and over 25 times greater for 5d−f. The other dominant
cytosolic isoform, hCA II, was inhibited by almost all selenides
with an inhibition constant in the medium nanomolar range,
except for compound 5a in the high nanomolar range (Ki = 6.3
to 355 nM). An interesting inhibition profile was observed for
the mitochondrial isoform hCA VA. All compounds were
potent inhibitors with an activity in the low nanomolar range
(Ki = 2.9 to 8.8 nM). However, the small and cyclic moieties
found in 5c, 5d, and 5i led to less active inhibitors. This
potency was substantially higher than those for the reported
standards; thus, these compounds were excellent candidates for
follow-up cell-based studies. In addition, the second mitochon-
drial isoform hCA VB was also well inhibited by almost all
selenides reported here. An interesting case was offered by
compound 5a with 5j. The difference in structure is a hydroxyl
group versus a methoxy moiety, respectively. However,
compound 5a proved to be nearly 10-fold less potent than
5j. The last cytosolic human isoform here studied, hCA VII,
was also strongly inhibited by selenides 5a−j with inhibition
constants spanning from the subnanomolar (Ki = 0.24 nM) to
the medium nanomolar range (Ki = 27.4 nM). Compound 5a,
this time, showed a potency of inhibition 35-fold less than that
of the compound incorporating the methoxyl tail (5j). The
transmembrane isoform hCA IX was effectively inhibited by all
compounds here reported with Kis in the range of 2.2−12 nM.
The SAR is almost absent in this case, as all selenides showed a
very comparable behavior as potent hCA IX inhibitors. In
addition, hCA IX is not only implicated in ischemia-induced
cerebrovascular pathology14 but its expression is upregulated in
a wide type of hypoxic tumors. Thus, several of these
compounds may have potential as anticancer therapeutics.
Complex of hCA II/Selenides Ligand Complex. The
protein complex with compound 5e was determinate by X-ray
crystal structure, and we had obtained ligand−protein
Scheme 2. Synthesis of Selenides 5a−j Bearing
Benzenesulfonamide Moieties
Scheme 3. Synthesis of 4-
(Bromomethyl)benzenesulfonamide 7
Scheme 4. Synthesis of 4-
((Phenylselanyl)methyl)benzenesulfonamide 9
Table 2. Inhibition Data of Human CA Isoforms I, II, IV,
VA, VB, VII, and IX with Compounds 2, 3, 5a−j, 9, AAZ,
and TPM by a Stopped Flow CO2 Hydrase Assay
26
Ki (nM)
a
Compound hCAI hCA II hCAVA hCAVB hCA VII hCAIX
2 95.6 53.1 8.2 5.7 7.1 9.3
3 1522.7 7.9 7.3 5.7 40.5 2.7
5a 338.3 355.3 5.4 46.8 27.1 2.4
5b 256.8 9.3 5.1 36.0 0.31 8.7
5c 352.2 73.2 7.3 31.3 4.6 2.7
5d 9.7 69.9 7.1 5.7 0.28 2.4
Se 5.2 36.5 6.9 45.1 0.27 2.6
5f 7.3 9.3 5.8 22.8 0.25 2.7
Sg 293.5 7.6 7.1 16.8 2.0 2.2
5h 297.1 70.8 2.9 12.3 0.38 2.6
5i 21.9 6.3 8.8 12.7 0.24 2.6
Sj 261.7 41.2 4.0 5.5 0.77 12.0
9 226.1 53.0 5.4 19.1 6.6 2.7
AAZ 250 10 63 54 2.5 25.8
TPM 250 10 63 30 9.0 58
aMean from three different assays, by a stopped flow technique (errors
were in the range of 5−10% of the reported values).
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interactions at the atomic level (Figure 3). hCA II was selected
as a model isoform for crystallization because it easily forms
crystals, and many studies have been reported on its structure
with different classes of inhibitors.32
Active site analysis of selenide 5e showed that the
sulfonamide moiety of inhibitor was tightly coordinated to
the Zn(II) ion by a binding mode to the protein similar to
other CAIs containing the same ZBG.32 Additionally, hydro-
phobic residues that are in relatively close proximity of the
inhibitor scaffold are shown around the alkyl chain of
compound 5e (Figure 3b).
Biological Assays. Some selected compounds (3, 5a, 5d,
5h, and 5j), chosen among those possessing an interesting
inhibitory profile against the mitochondrial hCA VA and VB,
were tested to evaluate their effects on the viability of rat brain
endothelial (RBE4) cells, cultured in oxidative stress conditions
in the presence of glucose oxidase (GOx). First of all, we
evaluated the cytotoxicity of the tested compounds against
RBE4, and the cell viability is shown in Figure 4.
Diselenide 3 was significantly cytotoxic, inducing a mortality
of about 50% at a concentration of 30 μM. All other selenides
here reported proved to be safe at low concentrations. One
should note that a decrease of cell viability was measured at
high concentrations (100 μM), after 24 h treatment with
compounds 5a and 5h. The safe compounds 5a, 5d, 5h, and 5j
were evaluated as possible scavengers of oxidative stress by
GOx. RBE4 cells were incubated with glucose oxidase in two
concentrations (0.1 and 0.3 U/mL) and selenides, and the
results are shown in Figure 5.
Cell viability of control decreases up to 40% with
enhancement of GOx. Among the tested compounds, only
selenide 5j showed good protection of cerebral endothelial cells
from GOx damage at the higher dose (100 μM). The other
selenides did not show any significant scavenger activity in
these assay conditions.
Conclusion. We have designed, synthesized, and obtained
an X-ray crystallographic structure of a novel series of selenides
bearing the benzenesulfonamide moieties, which behave as
potent mitochondrial CA inhibitors. Compound 5j proved to
be effective as a scavenger agent on RBE4 cell line. Selective
binding to mitochondrial CA is an important undertaking for
targeting diabetic cerebrovascular pathology and is challenging
with classical pharmacologically using sulfonamide/sulfamate
CA inhibitors. The findings reported here are of substantial
interest and highlight the potential of selenides bearing
benzenesulfonamide groups to be exploited for the discovery
of potent, mitochondrial-selective CA inhibitors. Thus, in the
future we will design new selenides with more selectivity and
protector attributes for viability of rat brain endothelial (RBE4)
cells.
Figure 3. Whole protein hCA II with 5e bound (A) and active site
region of the hCA II/5e complex (B) (PDB code: 6CEH).
Figure 4. RBE4 cell viability (4 × 104 cell/well) following 24 h
incubation with compounds 3, 5a, 5d, 5h, and 5j at 10, 30, and 100
μM. *p < 0.001 versus control.
Figure 5. RBE4 cells (4 × 104 cell/well) were incubated 1 h with GOx
(0.1, 0.3 U/mL) and 5a, 5d, 5h, and 5j (10 and 30 μM, also 100 μM,
when it was not cytotoxic), and the following 24 h, they recovered in
culture medium with the compounds at the same concentrations. **p
< 0.01, ***p < 0.001 versus control; ^p < 0.05 vs GOX 0.1 U/mL.
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